Shopping Cart
Remove All
Your shopping cart is currently empty
Acetyl Gastric Inhibitory Peptide (human) TFA
Copy Product Info
😃Good
Catalog No. T78543
Alias Human N-acetyl GIP TFA
Acetyl Gastric Inhibitory Peptide (human) TFA, a fatty acid-derivatized analog of the glucose-dependent insulinotropic polypeptide, exhibits enhanced antihyperglycemic and insulinotropic properties. It is utilized in the research of diabetes, insulin resistance, and obesity [1] [2] [3].
Acetyl Gastric Inhibitory Peptide (human) TFA
Acetyl Gastric Inhibitory Peptide (human) TFA
Copy Product Info😃Good
Catalog No. T78543Alias Human N-acetyl GIP TFA
Acetyl Gastric Inhibitory Peptide (human) TFA, a fatty acid-derivatized analog of the glucose-dependent insulinotropic polypeptide, exhibits enhanced antihyperglycemic and insulinotropic properties. It is utilized in the research of diabetes, insulin resistance, and obesity [1] [2] [3].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Acetyl Gastric Inhibitory Peptide (human) TFA, a fatty acid-derivatized analog of the glucose-dependent insulinotropic polypeptide, exhibits enhanced antihyperglycemic and insulinotropic properties. It is utilized in the research of diabetes, insulin resistance, and obesity [1] [2] [3]. |
| In vitro | Acetyl Gastric Inhibitory Peptide (human) TFA induces cyclic adenosine monophosphate (cAMP) production in transfected Chinese hamster lung fibroblasts that express human GIP receptors, with an EC50 value of 1.9 nM [1]. Compared to natural GIP, Acetyl Gastric Inhibitory Peptide (human) TFA at concentrations ranging from 10-13 to 10-8 nM demonstrates potent effects in stimulating insulin release [1]. This compound can improve conditions such as glucose intolerance, type 2 diabetes, beta-cell glucose insensitivity, insulin resistance, and reduced insulin secretion [2]. Acetyl Gastric Inhibitory Peptide (human) TFA has the metabolic stability of two fatty acid-derived N-terminal acetylated GIP analogues, along with hypoglycemic and insulinotropic activities, and has been evaluated both in vitro and in vivo [3]. |
| In vivo | Acetyl Gastric Inhibitory Peptide (human) TFA administered at 25 nmol/kg via intraperitoneal injection as a single dose demonstrated resistance to degradation by plasma dipeptidyl peptidase IV, thereby enhancing its bioactivity and improving its potential as an antidiabetic agent in vivo [1]. |
| Synonyms | Human N-acetyl GIP TFA |
| Formula | C228H340N60O67S.C2HF3O2 |
| Sequence | H-DL-Tyr-DL-Ala-DL-Glu-Gly-DL-xiThr-DL-Phe-DL-xiIle-DL-Ser-DL-Asp-DL-Tyr-DL-Ser-DL-xiIle-DL-Ala-DL-Met-DL-Asp-DL-Lys-DL-xiIle-DL-His-DL-Gln-DL-Gln-DL-Asp-DL-Phe-DL-Val-DL-Asn-DL-Trp-DL-Leu-DL-Leu-DL-Ala-DL-Gln-DL-Lys-Gly-DL-Lys-DL-Lys-DL-Asn-DL-Asp-DL-Trp-DL-Lys-DL-His-DL-Asn-DL-xiIle-DL-xiThr-DL-Gln-OH |
| Sequence Short | YAEGXFXSDYSXAMDKXHQQDFVNWLLAQKGKKNDWKHNXXQ |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Acetyl Gastric Inhibitory Peptide (human) TFA | purchase Acetyl Gastric Inhibitory Peptide (human) TFA | Acetyl Gastric Inhibitory Peptide (human) TFA cost | order Acetyl Gastric Inhibitory Peptide (human) TFA | Acetyl Gastric Inhibitory Peptide (human) TFA in vivo | Acetyl Gastric Inhibitory Peptide (human) TFA in vitro | Acetyl Gastric Inhibitory Peptide (human) TFA formula
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.